Keystone Conference is ongoing. Norm Wong presents tomorrow, the last day of conference. Of interest, there are a number of BET inhibitor talks in tomorrow's session (see below). I asked Sarah if they plan to share the abstract and got a to-be-determined response.

As for the Dialysis Advances in Kidney Disease Conference that runs Feb 1-3, Sarah replied "A SVP from Resverlogix is attending this conference, however the company is not presenting." I did notice in the program that Kamyar Kalantar-Zadeh has a talk unrelated to Resverlogix at that conference.

Rab K. Prinjha, GlaxoSmithKline, UK

Clinical Progression of BET Inhibitors

Norm Wong, Resverlogix Corporation, Canada 

Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis

Shaokun Shu, Dana-Farber Cancer Institute, USA 

Short Talk: Response and Resistance to BET Bromodomain Inhibitors in Triple Negative Breast Cancer

Erica Korb, Rockefeller University, USA 

Short Talk: Treatment of Fragile X Syndrome with the BET Inhibitor Jq1